Whitehawk Q3 Loss Widens to $21.2 Million as Third ADC Enters Clinic
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million on November 9, 2026, up from $17.7 million a year earlier, and disclosed in its results release that its third antibody-drug conjugate (ADC) program had entered clinical testing. The clinical-stage company recorded no revenue in either third quarter. Research and development expense rose to $18.1 million from $14.3 million. Selling, general and administrative expense declined, partly offsetting the R&D increase…